✦ LIBER ✦

Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis

✍ Scribed by Y.-F. Liaw; C.-M. Lee; R.-N. Chien; C.-T. Yeh

Book ID: 108885846
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 412 KB
Volume: 13
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2005.00687.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Emergence of adefovir-resistant mutants

Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy

✍ Hyeok Choon Kwon; Jae Youn Cheong; Sung Won Cho; Jae Myoung Choi; Sun Pyo Hong; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

Loss of lamivudine resistance mutations

Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy

✍ Christopher Westland; Craig Gibbs; Michael Miller; Mark Sullivan; John Fry; Caro 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Efficacy of adefovir add-on lamivudine r

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B

✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45

Increased risk of adefovir resistance in

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy

✍ Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu L 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood. We compared the emergence of the ADV-resistant mutations rt

740 Emergence of dual-resistance HBV mut

740 Emergence of dual-resistance HBV mutations to adefovir-dipivoxil and lamivudine in a hepatitis B patient with combination therapy for adefovir resistance

✍ S.Y. Kwon; C.H. Lee; W.H. Choi; J.E. Yeon; K.S. Byun 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Mutations associated with the therapeuti

Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis

✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated